The drugmakers Sanofi and GSK have announced they will request emergency use authorization for their COVID-19 vaccine from European and U.S. regulators.
Geneva, February 25 (RHC)-- The drugmakers Sanofi and GSK have announced they will request emergency use authorization for their COVID-19 vaccine from European and U.S. regulators.
The companies say the Sanofi-GSK vaccine showed 100% efficacy at preventing severe disease and hospitalization in a late-state clinical trial and 58% efficacy against symptomatic disease.
Sanofi and GSK received billions of dollars from Operation Warp Speed, the Trump administration’s initiative to fast-track vaccine development.
